X4 Pharmaceuticals, Inc.
XFOR
$0.21
-$0.0016-0.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.56M | 1.12M | 563.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.56M | 1.12M | 563.00K | -- | -- |
| Cost of Revenue | 797.00K | 495.00K | 268.00K | -- | -- |
| Gross Profit | 1.76M | 628.00K | 295.00K | -- | -- |
| SG&A Expenses | 61.52M | 56.30M | 48.77M | 45.70M | 35.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.96M | 132.01M | 124.16M | 115.51M | 107.52M |
| Operating Income | -141.40M | -130.89M | -123.60M | -115.51M | -107.52M |
| Income Before Tax | -37.14M | -16.67M | 17.73M | -128.82M | -101.09M |
| Income Tax Expenses | 310.00K | 85.00K | 96.00K | 93.00K | 78.00K |
| Earnings from Continuing Operations | -37.45 | -16.76 | 17.63 | -128.91 | -101.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.45M | -16.76M | 17.63M | -128.91M | -101.17M |
| EBIT | -141.40M | -130.89M | -123.60M | -115.51M | -107.52M |
| EBITDA | -140.61M | -130.30M | -123.18M | -115.15M | -107.10M |
| EPS Basic | -0.18 | -0.08 | 0.09 | -0.70 | -0.60 |
| Normalized Basic EPS | -0.44 | -0.38 | -0.27 | -0.44 | -0.38 |
| EPS Diluted | -0.19 | -0.09 | 0.08 | -0.70 | -0.60 |
| Normalized Diluted EPS | -0.44 | -0.38 | -0.27 | -0.44 | -0.38 |
| Average Basic Shares Outstanding | 804.23M | 800.06M | 796.19M | 764.48M | 710.46M |
| Average Diluted Shares Outstanding | 804.59M | 800.42M | 796.55M | 764.48M | 710.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
